Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Sam Fine O Chem Ltd

    Sam Fine O Chem Limited (An ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007 Certified Company) was established in year 2005 is a state of art manufacturing facility, located at

  • No Image
    Samrat Pharmachem Ltd

    Samrat Pharmachem Limited was incorporated on 16th June, 1992, at Ankleshwar in Gujarat State of India. It was promoted by Mr. Lalit Mehta & Mr. Rajesh Mehta The Company is curr

  • No Image
    Samrat Remedies Ltd

    Samrat Remedies Ltd incorporated in 2003 is engaged in the manufacture of iodine derivatives and has an installed capacity of 480 MT per annum. These are used by pharmaceutical

  • No Image
    Sandu Pharmaceuticals Ltd

    Sandu' is an ISO 9001:2000 certified group of companies established in 1899 specializing in manufacture and marketing of Ayurvedic medicines and is blessed with a rich heritage